Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

How vaccinia virus has evolved to subvert the host immune response.

Bahar MW, Graham SC, Chen RA, Cooray S, Smith GL, Stuart DI, Grimes JM.

J Struct Biol. 2011 Aug;175(2):127-34. doi: 10.1016/j.jsb.2011.03.010. Review.

2.

A novel respiratory model of infection with monkeypox virus in cynomolgus macaques.

Goff AJ, Chapman J, Foster C, Wlazlowski C, Shamblin J, Lin K, Kreiselmeier N, Mucker E, Paragas J, Lawler J, Hensley L.

J Virol. 2011 May;85(10):4898-909. doi: 10.1128/JVI.02525-10.

3.

Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity.

Haller O, Kochs G.

J Interferon Cytokine Res. 2011 Jan;31(1):79-87. doi: 10.1089/jir.2010.0076. Review.

PMID:
21166595
4.

Update on new antivirals under development for the treatment of double-stranded DNA virus infections.

Dropulic LK, Cohen JI.

Clin Pharmacol Ther. 2010 Nov;88(5):610-9. doi: 10.1038/clpt.2010.178. Review.

5.

Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo.

Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, Blumberg S, Thomassen HA, Pike BL, Fair JN, Wolfe ND, Shongo RL, Graham BS, Formenty P, Okitolonda E, Hensley LE, Meyer H, Wright LL, Muyembe JJ.

Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16262-7. doi: 10.1073/pnas.1005769107.

6.

Dynamin-like MxA GTPase: structural insights into oligomerization and implications for antiviral activity.

Haller O, Gao S, von der Malsburg A, Daumke O, Kochs G.

J Biol Chem. 2010 Sep 10;285(37):28419-24. doi: 10.1074/jbc.R110.145839. Review.

7.

Tecovirimat for smallpox infections.

Bolken TC, Hruby DE.

Drugs Today (Barc). 2010 Feb;46(2):109-17. doi: 10.1358/dot.2010.46.2.1437244.

PMID:
20393639
8.

The highly virulent variola and monkeypox viruses express secreted inhibitors of type I interferon.

Fernández de Marco Mdel M, Alejo A, Hudson P, Damon IK, Alcami A.

FASEB J. 2010 May;24(5):1479-88. doi: 10.1096/fj.09-144733.

9.
10.

Smallpox vaccines for biodefense.

Kennedy RB, Ovsyannikova I, Poland GA.

Vaccine. 2009 Nov 5;27 Suppl 4:D73-9. doi: 10.1016/j.vaccine.2009.07.103. Review.

11.

The interferon response circuit in antiviral host defense.

Haller O, Weber F.

Verh K Acad Geneeskd Belg. 2009;71(1-2):73-86. Review.

PMID:
19739399
12.

The interferon system and vaccinia virus evasion mechanisms.

Perdiguero B, Esteban M.

J Interferon Cytokine Res. 2009 Sep;29(9):581-98. doi: 10.1089/jir.2009.0073. Review.

PMID:
19708815
13.

Vaccinia virus K1L and C7L inhibit antiviral activities induced by type I interferons.

Meng X, Jiang C, Arsenio J, Dick K, Cao J, Xiang Y.

J Virol. 2009 Oct;83(20):10627-36. doi: 10.1128/JVI.01260-09.

14.

Proteomic screening of variola virus reveals a unique NF-kappaB inhibitor that is highly conserved among pathogenic orthopoxviruses.

Mohamed MR, Rahman MM, Lanchbury JS, Shattuck D, Neff C, Dufford M, van Buuren N, Fagan K, Barry M, Smith S, Damon I, McFadden G.

Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9045-50. doi: 10.1073/pnas.0900452106.

15.

Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.

Huggins J, Goff A, Hensley L, Mucker E, Shamblin J, Wlazlowski C, Johnson W, Chapman J, Larsen T, Twenhafel N, Karem K, Damon IK, Byrd CM, Bolken TC, Jordan R, Hruby D.

Antimicrob Agents Chemother. 2009 Jun;53(6):2620-5. doi: 10.1128/AAC.00021-09.

16.

ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.

Jordan R, Goff A, Frimm A, Corrado ML, Hensley LE, Byrd CM, Mucker E, Shamblin J, Bolken TC, Wlazlowski C, Johnson W, Chapman J, Twenhafel N, Tyavanagimatt S, Amantana A, Chinsangaram J, Hruby DE, Huggins J.

Antimicrob Agents Chemother. 2009 May;53(5):1817-22. doi: 10.1128/AAC.01596-08.

17.

Inhibition of a large double-stranded DNA virus by MxA protein.

Netherton CL, Simpson J, Haller O, Wileman TE, Takamatsu HH, Monaghan P, Taylor G.

J Virol. 2009 Mar;83(5):2310-20. doi: 10.1128/JVI.00781-08.

18.

Monkeypox virus and insights into its immunomodulatory proteins.

Weaver JR, Isaacs SN.

Immunol Rev. 2008 Oct;225:96-113. doi: 10.1111/j.1600-065X.2008.00691.x. Review.

19.

Differential effects of the type I interferons alpha4, beta, and epsilon on antiviral activity and vaccine efficacy.

Day SL, Ramshaw IA, Ramsay AJ, Ranasinghe C.

J Immunol. 2008 Jun 1;180(11):7158-66.

20.
Items per page

Supplemental Content

Support Center